ClinicalTrials.gg
TerminatedNCT05255601RELATIVITY-069Updated Jun 26, 2026Results posted

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

A Phase 1/2 interventional study of Relatlimab and Nivolumab in Lymphoma, Non-Hodgkin and Hodgkin Disease, sponsored by Bristol-Myers Squibb. Terminated at 51 sites in 7 countries. Open to participants aged Up to 30 Years. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
Up to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing nivolumab in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, none of them phase 3. Nivolumab · Lymphoma, Non-Hodgkin.

Enrollment
12th of 12
5 · median 109
Started
2022
with 1 other
Phase 1/2
3 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
3 of 12
Bristol-Myers Squibb

Among the 12 studies testing nivolumab in Lymphoma, Non-Hodgkin, this one is the 12th largest by enrollment, is one of 2 that started in 2022, is one of 3 in phase 1/2, and was the 12th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

3 of the 12 studies testing nivolumab in Lymphoma, Non-Hodgkin are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: Up to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing nivolumab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.

03

Conditions studied

  • Lymphoma, Non-Hodgkin
  • Hodgkin Disease

Keywords

  • Pediatric
  • Lymphoma, Non-Hodgkin
  • Hodgkin Disease
  • Relatlimab
  • Nivolumab
  • Lymphocyte Activation Gene-3
  • Lymphoma, Large B-Cell, Diffuse
  • Primary Mediastinal B-cell Lymphoma
  • Lymphoma, Large-Cell, Anaplastic
  • Burkitt lymphoma
  • Lymphoblastic lymphoma
  • NK/ T-cell lymphoma
  • Peripheral T-cell lymphoma
04

Who can participate

Ages eligible
Up to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with confirmed high-risk R/R cHL, after non-response to or failure of 1or more lines of standard therapy.
  • Participants with pathologically confirmed R/R NHL after non-response to or failure of 1or more lines of standard therapy, including, but not limited to, R/R primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), mediastinal gray zone lymphoma (MGZL), anaplastic large cell lymphoma (ALCL), or peripheral T-cell lymphoma (PTCL).
  • Participants with pathologically confirmed R/R NHL after non-response to or failure of 2 or more lines of standard therapy, including Burkitt lymphoma (blast count \<25% malignant Burkitt cells and/or per the investigator's clinical assessment of risk status), lymphoblastic lymphoma (blast count \< 25% of marrow nucleated cells and/or per the investigator's clinical assessment of risk status), NK/T-cell lymphoma (nasal and non-nasal NK/T-cell lymphoma subtypes, but not aggressive NK/T-cell leukemia/lymphoma subtype).
  • The participant's current disease state must be R/R to standard therapy.
  • Participants must have measurable PET positive disease in both cHL and NHL cohorts.

Exclusion criteria

Exclusion Criteria:

  • Primary CNS lymphoma of the brain or spinal cord, and secondary CNS lymphoma (ie, from systemic non-Hodgkin lymphoma) involving the brain, spinal cord, or with seeding.
  • Prior treatment with an anti-cytotoxic T-lymphocyte-associated protein 4 () antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, with the exception of anti-PD(L)-1 targeted therapies.
  • Prior treatment with lymphocyte activation gene-3 (LAG-3)-targeted agents.
  • Participants with systemic illnesses unrelated to the cancer as judged by the investigators, which would compromise the participant's ability to tolerate the study treatment.
  • Participants with disease.
  • Prior bone marrow transplantation.

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Relatlimab + Nivolumab

    Drug: Relatlimab · Drug: Nivolumab

Interventions

  • Specified Dose on Specified Days

    Also known as: BMS-986016

  • Specified Dose on Specified Days

    Also known as: BMS-936558

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities (DLTs) - Part A

    Hepatic DLT * ALT or AST \> 8 × ULN * ALT or AST \> 5 and ≤ 8 × ULN, that fails to return to ≤ Grade 1 within 2 weeks despite medical intervention. * TB \> 5 × ULN. * ALT or AST \> 3 × ULN and concurrent total bilirubin \> 2 × ULN. Non-Hematologic DLT * ≥ Grade 2 episcleritis, uveitis, iritis or any other immune-related eye pain or reduction in visual acuity that requires systemic treatment. * ≥ Grade 3 non-hepatic or non-hematologic toxicity with the exceptions noted below. Hematologic DLT * Grade 4 anemia not explained by underlying disease. * Grade 3 febrile neutropenia lasting \> 48 hours, or Grade 4 febrile neutropenia * Grade 4 neutropenia that does not resolve to Grade 3 or less within 5 days of initiation of granulocyte colony stimulating factor. * Grade 3 thrombocytopenia associated with clinically significant bleeding. * Grade 3 hemolysis

    Time frame: 1 cycle, defined as 28 days

  2. Complete Metabolic Response (CMR) Rate - Part B

    The CMR rate is defined as the percentage of all response-evaluable participants who achieve the best response of CMR using Lugano 2014 criteria. No participants enrolled in Part B.

    Time frame: From first dose until the first documented response

  3. Number of Participants With Adverse Events (AEs) - Part A

    An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose to 135 days post last dose (Up to approximately 11 months)

  4. Number of Participants Who Died - Part A

    Number of participants who died due to any cause

    Time frame: from first dose to 135 days post last dose (Up to approximately 11 months)

  5. Number of Participants With Serious Adverse Events (SAEs) - Part A

    Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: from first dose to 135 days post last dose (Up to approximately 11 months)

  6. Number of Participants With Adverse Events (AEs) Leading to Discontinuation - Part A

    An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose to 135 days post last dose (Up to approximately 11 months)

  7. Number of Participants With Laboratory Abnormalities - Part A

    Number of participants with Grade ≥ 3 laboratory abnormalities in hematology and serum chemistry. Grade 3=severe Grade 4=life-threatening Grade 5=death

    Time frame: From first dose to 30 days post last dose (Up to approximately 8 months)

  8. Maximum Serum Concentration (Cmax)

    Maximum observed serum concentration of Analyte BMS-986016

    Time frame: Cycle 1 Day 1

  9. Time to Maximum Concentration (Tmax)

    Time of maximum observed serum concentration of Analyte BMS-986016

    Time frame: Cycle 1 Day 1

  10. Area Under the Concentration-time Curve [AUC(TAU)]

    Area Under the Concentration-time Curve \[AUC(TAU)\] for Analyte BMS-986016

    Time frame: Cycle 1 Day 1

  11. Concentration Trough (Ctrough)

    Concentration Trough (Ctrough) for Analyte BMS-986016 and BMS-936558

    Time frame: Cycle 2 Day 1, Cycle 4 Day 1, Cycle 6 Day 1

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs) - Part B

    An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment. No participants enrolled in part B.

    Time frame: From first dose to 135 days post last dose

  2. Number of Participants With Serious Adverse Events (SAEs) - Part B

    Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization. No participants enrolled in part B.

    Time frame: From first dose to 135 days post last dose

  3. Number of Participants With Adverse Events Leading to Discontinuation - Part B

    An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment. No participants enrolled in part B.

    Time frame: From first dose to 135 days post last dose

  4. Number of Participants Who Died - Part B

    Number of participants who died due to any cause. No participants enrolled in part B.

    Time frame: From first dose to 135 days post last dose

  5. Number of Participants With Laboratory Abnormalities - Part B

    No participants enrolled in part B.

    Time frame: From first dose to 135 days post last dose

  6. Objective Response Rate (ORR) - Part B

    ORR is defined as the percentage of all response evaluable participants who achieve a best response of CMR or PMR using the Lugano 2014 classification. No participants enrolled in part B

    Time frame: From to

07

Results

Posted Jun 26, 2026

Participant flow

Participant flow — Overall Study
MilestonePart A - Flat Dosing (AF)Part A - Age/Weight-based Dosing (AW)
Started41
Completed00
Not completed41
Withdrew: Other reasons10
Withdrew: Maximum clinical benefit10
Withdrew: Disease progression21

Outcome measures

SecondaryNumber of Participants With Adverse Events (AEs) - Part B

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment. No participants enrolled in part B.

Time frame:
From first dose to 135 days post last dose
Reported as:
Count of participants · Participants

No measurements were reported for this outcome.

SecondaryNumber of Participants With Serious Adverse Events (SAEs) - Part B

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization. No participants enrolled in part B.

Time frame:
From first dose to 135 days post last dose
Reported as:
Count of participants · Participants

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events Leading to Discontinuation - Part B

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment. No participants enrolled in part B.

Time frame:
From first dose to 135 days post last dose
Reported as:
Count of participants · Participants

No measurements were reported for this outcome.

SecondaryNumber of Participants Who Died - Part B

Number of participants who died due to any cause. No participants enrolled in part B.

Time frame:
From first dose to 135 days post last dose
Reported as:
Count of participants · Participants

No measurements were reported for this outcome.

SecondaryNumber of Participants With Laboratory Abnormalities - Part B

No participants enrolled in part B.

Time frame:
From first dose to 135 days post last dose
Reported as:
Count of participants · Participants

No measurements were reported for this outcome.

PrimaryNumber of Participants With Dose-Limiting Toxicities (DLTs) - Part A

Hepatic DLT * ALT or AST \> 8 × ULN * ALT or AST \> 5 and ≤ 8 × ULN, that fails to return to ≤ Grade 1 within 2 weeks despite medical intervention. * TB \> 5 × ULN. * ALT or AST \> 3 × ULN and concurrent total bilirubin \> 2 × ULN. Non-Hematologic DLT * ≥ Grade 2 episcleritis, uveitis, iritis or any other immune-related eye pain or reduction in visual acuity that requires systemic treatment. * ≥ Grade 3 non-hepatic or non-hematologic toxicity with the exceptions noted below. Hematologic DLT * Grade 4 anemia not explained by underlying disease. * Grade 3 febrile neutropenia lasting \> 48 hours, or Grade 4 febrile neutropenia * Grade 4 neutropenia that does not resolve to Grade 3 or less within 5 days of initiation of granulocyte colony stimulating factor. * Grade 3 thrombocytopenia associated with clinically significant bleeding. * Grade 3 hemolysis

Time frame:
1 cycle, defined as 28 days
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities (DLTs) - Part A
ParticipantsPart A - Flat Dosing (AF)Part A - Age/Weight-based Dosing (AW)
Number of Participants With Dose-Limiting Toxicities (DLTs) - Part A00
PrimaryComplete Metabolic Response (CMR) Rate - Part B

The CMR rate is defined as the percentage of all response-evaluable participants who achieve the best response of CMR using Lugano 2014 criteria. No participants enrolled in Part B.

Time frame:
From first dose until the first documented response
Reported as:
Number · Percentage of participants

No measurements were reported for this outcome.

SecondaryObjective Response Rate (ORR) - Part B

ORR is defined as the percentage of all response evaluable participants who achieve a best response of CMR or PMR using the Lugano 2014 classification. No participants enrolled in part B

Time frame:
From to
Reported as:
Number · Percentage of participants

No measurements were reported for this outcome.

PrimaryNumber of Participants With Adverse Events (AEs) - Part A

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose to 135 days post last dose (Up to approximately 11 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) - Part A
ParticipantsPart A - Flat Dosing (AF)Part A - Age/Weight-based Dosing (AW)
Number of Participants With Adverse Events (AEs) - Part A41
PrimaryNumber of Participants Who Died - Part A

Number of participants who died due to any cause

Time frame:
from first dose to 135 days post last dose (Up to approximately 11 months)
Reported as:
Count of participants · Participants
Number of Participants Who Died - Part A
ParticipantsPart A - Flat Dosing (AF)Part A - Age/Weight-based Dosing (AW)
Number of Participants Who Died - Part A01
PrimaryNumber of Participants With Serious Adverse Events (SAEs) - Part A

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
from first dose to 135 days post last dose (Up to approximately 11 months)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) - Part A
ParticipantsPart A - Flat Dosing (AF)Part A - Age/Weight-based Dosing (AW)
Number of Participants With Serious Adverse Events (SAEs) - Part A11
PrimaryNumber of Participants With Adverse Events (AEs) Leading to Discontinuation - Part A

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose to 135 days post last dose (Up to approximately 11 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) Leading to Discontinuation - Part A
ParticipantsPart A - Flat Dosing (AF)Part A - Age/Weight-based Dosing (AW)
Number of Participants With Adverse Events (AEs) Leading to Discontinuation - Part A00
PrimaryNumber of Participants With Laboratory Abnormalities - Part A

Number of participants with Grade ≥ 3 laboratory abnormalities in hematology and serum chemistry. Grade 3=severe Grade 4=life-threatening Grade 5=death

Time frame:
From first dose to 30 days post last dose (Up to approximately 8 months)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities - Part A
ParticipantsPart A - Flat Dosing (AF)Part A - Age/Weight-based Dosing (AW)
Grade ≥ 3 Hematology10
Grade ≥ 3 Serum Chemistry00
PrimaryMaximum Serum Concentration (Cmax)

Maximum observed serum concentration of Analyte BMS-986016

Time frame:
Cycle 1 Day 1
Reported as:
Geometric mean · ug/mL
Maximum Serum Concentration (Cmax)
ug/mLPart A - Flat Dosing (AF)Part A - Age/Weight-based Dosing (AW)
Maximum Serum Concentration (Cmax)51.83 ± 1640.00 ± NA
PrimaryTime to Maximum Concentration (Tmax)

Time of maximum observed serum concentration of Analyte BMS-986016

Time frame:
Cycle 1 Day 1
Reported as:
Median · hour
Time to Maximum Concentration (Tmax)
hourPart A - Flat Dosing (AF)Part A - Age/Weight-based Dosing (AW)
Time to Maximum Concentration (Tmax)0.74 (0.58 to 1.00)0.50 (0.50 to 0.50)
PrimaryArea Under the Concentration-time Curve [AUC(TAU)]

Area Under the Concentration-time Curve \[AUC(TAU)\] for Analyte BMS-986016

Time frame:
Cycle 1 Day 1
Reported as:
Geometric mean · h*ug/mL
Area Under the Concentration-time Curve [AUC(TAU)]
h*ug/mLPart A - Flat Dosing (AF)Part A - Age/Weight-based Dosing (AW)
Area Under the Concentration-time Curve [AUC(TAU)]13160.63 ± 326745.58 ± NA
PrimaryConcentration Trough (Ctrough)

Concentration Trough (Ctrough) for Analyte BMS-986016 and BMS-936558

Time frame:
Cycle 2 Day 1, Cycle 4 Day 1, Cycle 6 Day 1
Reported as:
Geometric mean · ug/mL
Concentration Trough (Ctrough)
ug/mLPart A - Flat Dosing (AF)Part A - Age/Weight-based Dosing (AW)
Cycle 2 Day 1 - BMS9860169.50 ± 682.39 ± NA
Cycle 4 Day 1 - BMS98601620.52 ± 66—
Cycle 6 Day 1 - BMS98601623.53 ± NA—
Cycle 2 Day 1 - BMS-93655840.32 ± 4617.80 ± NA
Cycle 4 Day 1 - BMS-93655879.80 ± 53—
Cycle 6 Day 1 - BMS-93655891.87 ± NA—

Adverse events

Collected over All-Cause Mortality (ACM) was assessed from randomization until their study completion (Up to approximately 38 months). Adverse Events (AEs) and Serious Adverse (SAEs) were assessed from first dose to 135 days post last dose (Up to approximately 11 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A - Flat Dosing (AF)0/4 (0%)1/4 (25%)4/4 (100%)
Part A - Age/Weight-based Dosing (AW)1/1 (100%)1/1 (100%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventPart A - Flat Dosing (AF)Part A - Age/Weight-based Dosing (AW)
Facial painGeneral disorders and administration site conditions0/41/1
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/41/1
Spinal cord compressionNervous system disorders0/41/1
Skin infectionInfections and infestations1/40/1
Most frequent other events
Showing 10 of 47
Most frequent other events
EventPart A - Flat Dosing (AF)Part A - Age/Weight-based Dosing (AW)
ToothacheGastrointestinal disorders0/41/1
PyrexiaGeneral disorders and administration site conditions1/41/1
Otitis mediaInfections and infestations0/41/1
AnaemiaBlood and lymphatic system disorders2/40/1
LymphopeniaBlood and lymphatic system disorders2/40/1
DiarrhoeaGastrointestinal disorders2/40/1
HypoalbuminaemiaMetabolism and nutrition disorders2/40/1
Febrile neutropeniaBlood and lymphatic system disorders1/40/1
ThrombocytopeniaBlood and lymphatic system disorders1/40/1
HyperthyroidismEndocrine disorders1/40/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part A - Flat Dosing (AF)Part A - Age/Weight-based Dosing (AW)Total
<=18 years415
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Part A - Flat Dosing (AF)Part A - Age/Weight-based Dosing (AW)Total
Female101
Male314
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A - Flat Dosing (AF)Part A - Age/Weight-based Dosing (AW)Total
Hispanic or Latino000
Not Hispanic or Latino213
Unknown or Not Reported202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A - Flat Dosing (AF)Part A - Age/Weight-based Dosing (AW)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White404
More than one race000
Unknown or Not Reported000
08

Study locations

51 sites
  • Local Institution - 0077
    Birmingham, Alabama 35233, United States
  • Local Institution - 0024
    Phoenix, Arizona 85016, United States
  • Local Institution - 0035
    Palo Alto, California 94304, United States
  • Local Institution - 0032
    New Haven, Connecticut 06510, United States
  • Local Institution - 0066
    Fort Myers, Florida 33908, United States
  • Local Institution - 0073
    Baltimore, Maryland 21287, United States
  • Local Institution - 0025
    Minneapolis, Minnesota 55454, United States
  • Local Institution - 0020
    Jackson, Mississippi 39216, United States
  • Local Institution - 0071
    Hackensack, New Jersey 07601, United States
  • Local Institution - 0060
    New York, New York 10032, United States
  • Local Institution - 0059
    Valhalla, New York 10595, United States
  • Local Institution - 0029
    Austin, Texas 78723, United States
  • Local Institution - 0026
    San Antonio, Texas 78207, United States
  • Local Institution - 0037
    Randwick, New South Wales 2031, Australia
  • Royal Childrens Hospital RCH - Queensland Childrens Hospital
    South Brisbane, Queensland 4101, Australia
  • Local Institution - 0042
    Nedlands, Western Australia 6009, Australia
  • CHU dAngers - Pole Pediatrie
    Angers, Angers Cedex 9 49933, France
  • Groupe Hospitalier Pellegrin - Hopital des enfants
    Bordeaux, 33076, France
  • Local Institution - 0033
    Caen, 14033, France
  • Local Institution - 0067
    La Tronche, 38700, France
  • Institut d Hematologie et d Oncologie Pediatriques
    Lyon, 69373 Cedex 08, France
  • Centre Hospitalier Universitaire de Montpellier CHU Montpellier - Hopital Arnaud de Villeneuve
    Montpellier, 34295, France
  • Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Armand-Trousseau
    Paris, 75571, France
  • Assistance Publique-Hopitaux de Paris AP-HP - Hopital Universitaire Robert-Debre
    Paris, 75935, France
  • CHRU de Strasbourg-Hopital de Hautepierre
    Strasbourg, 67000, France
  • Fondazione IRCCS Istituto Nazionale Dei Tumori
    Milan, Milano 20133, Italy
  • Local Institution - 0010
    Aviano, 33081, Italy
  • Azienda Ospedaliero Universitaria di Bologna
    Bologna, 40138, Italy
  • Local Institution - 0040
    Florence, 50139, Italy
  • Local Institution - 0070
    Milan, 20162, Italy
  • Fondazione MBBM - Clinica Pediatrica
    Monza, 20900, Italy
  • Azienda Ospedale Universita Padova
    Padova, 35128, Italy
  • Local Institution - 0041
    Pavia, 27100, Italy
  • Local Institution - 0002
    Roma, 00165, Italy
  • Local Institution - 0004
    Turin, 10126, Italy
  • Princess Maxima Center for pediatric oncology
    Utrecht, 3584 CS, Netherlands
  • Local Institution - 0069
    Esplugues de Llobregat, Barcelona 08950, Spain
  • Local Institution - 0030
    Madrid, Madrid 28009, Spain
  • Local Institution - 0046
    Barcelona, 08035, Spain
  • Local Institution - 0058
    Madrid, 28027, Spain
  • Local Institution - 0044
    Madrid, 28040, Spain
  • Local Institution - 0055
    Madrid, 28041, Spain
  • Local Institution - 0045
    Madrid, 28046, Spain
  • Local Institution - 0062
    Pamplona, 31008, Spain
  • Local Institution - 0023
    Seville, 41013, Spain
  • Local Institution - 0049
    Valencia, 46026, Spain
  • Local Institution - 0075
    Cambridge, Cambridgeshire CB2 0QQ, United Kingdom
  • Local Institution - 0074
    Liverpool, England L12 2AP, United Kingdom
  • Local Institution - 0054
    London, Londonderry NW1 2PG, United Kingdom
  • Local Institution - 0068
    Newcastle upon Tyne, Tyne and Wear NE1 4LP, United Kingdom
  • Local Institution - 0053
    London, SM2 5PT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Dec 2025, 38 months.

Results were first posted in Jun 2026, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2022
First posted
Feb 24, 2022
StartActual
Sep 13, 2022
Primary completionActual
Dec 3, 2025
CompletionActual
Dec 3, 2025
Results first posted
Jun 26, 2026
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05255601
Responsible party
Sponsor
First posted
Feb 24, 2022
Start date
Sep 13, 2022
Primary completion
Dec 3, 2025
Completion
Dec 3, 2025
Results posted
Jun 26, 2026
Last update
Jun 26, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Relatlimab · Nivolumab

Start the discussion